Summit Therapeutics Inc.
SMMT
$18.95
$0.291.55%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -400.96% | -387.81% | -368.59% | -361.42% | -107.50% |
| Total Depreciation and Amortization | 89.66% | 64.04% | 29.90% | -4.59% | -35.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,158.87% | 1,039.35% | 967.68% | 1,067.92% | 241.87% |
| Change in Net Operating Assets | 605.14% | 102.96% | -9.47% | 17.83% | 31.82% |
| Cash from Operations | -121.82% | -127.25% | -138.87% | -112.20% | -84.66% |
| Capital Expenditure | 13.82% | -372.66% | -299.21% | -304.92% | -605.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -417.74% | 15.37% | 273.08% | 332.74% | -183.81% |
| Cash from Investing | -414.05% | 15.11% | 272.76% | 332.11% | -184.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 67.55% | -- | -- |
| Issuance of Common Stock | 25.64% | 28.32% | -90.85% | 39.92% | 6,539.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 57.99% | 61.99% | -95.11% | -8.08% | 5,540.71% |
| Foreign Exchange rate Adjustments | -19.64% | 666.67% | -96.41% | 34.62% | -84.40% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -169.90% | 256.60% | 105.92% | 2,116.44% | 1,705.40% |